DB
ABUS icon

Dmitry Balyasny’s Arbutus Biopharma ABUS Stock Holding History

Dmitry Balyasny’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-125,521
Closed -$565K – 2955
2026
Q1 		$565K Sell
125,521
-16,125
-11% -$70.5K ﹤0.01% 2322
2025
Q4 		$681K Buy
141,646
+33,981
+32% +$153K ﹤0.01% 2373
2025
Q3 		$489K Buy
+107,665
New +$395K ﹤0.01% 2405
2025
Q2 		– Sell
-18,916
Closed -$66K – 2741
2025
Q1 		$66K Sell
18,916
-22,774
-55% -$75.9K ﹤0.01% 2703
2024
Q4 		$136K Buy
+41,690
New +$153K ﹤0.01% 2578
2023
Q1 		– Sell
-14,633
Closed -$34.1K – 2576
2022
Q4 		$34.1K Buy
14,633
+2,384
+19% +$5.7K ﹤0.01% 2404
2022
Q3 		$23K Buy
+12,249
New +$28.8K ﹤0.01% 2566
2021
Q2 		– Sell
-12,147
Closed -$40K – 1912
2021
Q1 		$40K Buy
+12,147
New +$46.9K ﹤0.01% 1689

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dmitry Balyasny's ABUS Position: Q2 2026 in Review

Dmitry Balyasny sold out of Arbutus Biopharma (ABUS) in Q2 2026, closing a stake of 125,521 shares — an estimated $565K sold.

Dmitry Balyasny first reported a position in ABUS in Q1 2021 and held it in 8 quarters. The position peaked at $681K in Q4 2025. 175 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Dmitry Balyasny reported no remaining Arbutus Biopharma position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 125,521 Arbutus Biopharma shares in Q2 2026, an estimated $565K.
  • Dmitry Balyasny first reported a position in Arbutus Biopharma in Q1 2021 and held it in 8 quarters.
  • Dmitry Balyasny's Arbutus Biopharma position peaked at $681K in Q4 2025.
  • 175 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.